CTAD 2022 Preview: Lecanemab Is Headliner After Gantenerumab’s Failure
Anti-Amyloid Debate Continues With Mixed Readouts
Phase III results for Eisai/Biogen’s lecanemab are the main event at the Clinical Trials on Alzheimer’s Disease meeting, but other data – even Roche’s failed Phase III gantenerumab studies – also may have implications for the amyloid-clearing antibody.
You may also be interested in...
Apellis’s pegcetacoplan – approved for two other indications – will not go forward in amyotrophic lateral sclerosis after a Phase II failure, two days after Wave Life made a similar call in the neurodegenerative disease.
Drug makers are more enthusiastic than ever about the outlook for developing drugs for Alzheimer's. Scrip reports back on the latest developments at CTAD.
Emerging Company Profile: The biotech plans to enter the clinic next year with a gene therapy targeting the E2F4 protein in the hopes of halting Alzheimer’s disease progression and restoring lost function.